Evidence map›Paper›PMID 31468129›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2019

Xylitol treats nasal mucosa in rhinitis medicamentosa: an experimental rat model study.

Behram Cam, Murat Sari, Ahmet Midi, Ozgül Gergin

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06830109 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Nasal Obstruction Randomized Trial With Oxymetazoline and Corticosteroids

TypeinterventionalSponsorWashington University School of MedicineRan2024 to 2026Enrolled80ConditionsNasal ObstructionArmsOxymetazoline Nasal Spray, Budesonide nasal spray
NCT07168148 phase2terminatednot on this mapstarted 2025, after this paper: background citation

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

TypeinterventionalSponsorWashington University School of MedicineRan2025 to 2026Enrolled3ConditionsNasal Obstruction, Chronic RhinitisArmsOxymetazoline + Triamcinolone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Platelet-Rich Plasma for Rhinitis Medicamentosa: A Promising Histopathological Study in an Animal Model.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Behram CamDepartment of Ear Nose Throat, Acibadem Healthcare Group, Acibadem Kocaeli Hospital, Izmit, Kocaeli, Turkey.
Murat SariDepartment of Ear Nose Throat, Marmara University, Ministry of Health, Pendik Education and Research Hospital, Istanbul, Turkey.
Ahmet MidiDepartment of Pathology, Istanbul Bahcesehir University, Faculty of Medicine, Sahrayı cedid mah, Batman sok, no 66, Göztepe, Kadıköy, Istanbul, Turkey. ahmetmidi@yahoo.com.ORCID http://orcid.org/0000-0002-6197-7654
Ozgül GerginDepartment of Ear Nose Throat, Ministry of Health, Ümraniye Education and Research Hospital, Istanbul, Turkey.
Ministry of Health · TRAcıbadem University · TRBahçeşehir University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRhinitis medicamentosa is drug-induced rhinitis which occurs by prolonged and overdose usage of topical nasal decongestants. There is not much of treatment choice rather than nasal steroids. In this pathological study, we have been aimed to represent the healing effects of xylitol on damaged nasal mucosa due to rhinitis medicamentosa.

method30 Wistar rats were separated into 5 groups. During 2 months, oxymetazoline was given to the first group, and saline was given to second group intranasally. First and second group animals were examined at the end of 2 months and rhinitis medicamentosa was detected. Oxymetazoline was given to the third, fourth, and fifth groups during 2 months. Then xylitol solution, mometasone, and saline were applied, respectively, for 15 days. After the experiment, rats' nasal mucosas were evaluated histopathologically.

resultsXylitol and mometasone were found to be more effective than the control group in terms of histopathological changes. Effectivity of xylitol and mometasone was compared and not a significant value was determined.

conclusionsAccording to the results, xylitol solution is effective as mometasone, usable and well-priced in the treatment of rhinitis medicamentosa. More comprehensive and ultrastructural studies on animals and human studies with rhinometric evaluation should be performed.

Indexed as

Nasal MucosaRhinitisAdministration, IntranasalAnimalsAnti-Inflammatory AgentsDisease Models, AnimalMaleMometasone FuroateNasal DecongestantsOxymetazolineRatsRats, WistarSweetening AgentsTimeTreatment OutcomeXylitolAnti-Inflammatory AgentsMometasone FuroateNasal DecongestantsOxymetazolineSweetening AgentsXylitolMometasoneNasal decongestantsNasal mucosaRhinitis medicamentosaXylitol

Identifiers

PMID31468129
OpenAlexW2970829248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.